The first of two ESC 2019 posters is now up and can be accessed here. "BET-inhibition with Apabetalone in Post-ACS Patients with Diabetes: Design and Baseline Characteristics of the BETonMACE Trial"
https://www.resverlogix.com/upload/media_element/177/76b2a9c98699/2019-09-02-esc-design-poster-final.pdf
Nothing new that we didn't see in previous BETonMACE design/baseline posters and/or the recently published paper.
https://www.sciencedirect.com/science/article/abs/pii/S0002870319301978
BearDownAZ